We analyzed a group of 51 patients with primary refractory and relapsed intermediate-grade lymphoma (IGL) from the time of initiation of three cycles of second-line chemotherapy, ifosfamide, carboplatin and etoposide (ICE), in whom the intent was to administer curative high-dose chemoradiotherapy and autologous stem cell transplantation (ASCT). We sought to determine if the International Prognostic Index (IPI) assessed immediately prior to ICE, second-line IPI (sIPI), was predictive of outcome. The response rate to ICE-based chemotherapy was 69%, and 47% of the transplanted patients remain failure-free at 2.5 years. Stratification of patients based upon the sIPI demonstrated a superior 2.5 year failure-free survival (FFS) curve for patients with low (I) or low-intermediate (II) risk disease vs those with high-intermediate (III) and high (IV) risk disease (45% vs 9%, P Ͻ 0.001). When the analysis was restricted to those patients with chemosensitive disease, the sIPI (I/II vs III/IV) also separated patients into two distinct prognostic groups (59% vs 20%, P ‫؍‬ 0.04). Patients with sIPI I and II disease have a favorable outcome with ICE chemotherapy and ASCT. However, patients with sIPI III and IV disease derive limited benefit from this treatment strategy, and new approaches are needed in this patient group. Keywords: intermediate-grade lymphoma; International Prognostic Index; ASCT Despite advances in the therapy of intermediate-grade nonHodgkin's lymphoma (IGL), more than half of patients either fail to a achieve a complete remission or relapse after receiving standard front-line therapy.
bone marrow transplantation (ABMT) vs conventional-dose second-line chemotherapy demonstrated the superiority of the high-dose treatment in terms of disease-free and overall survival. 2 Early studies of ASCT for IGL determined that sensitivity to conventional-dose second-line chemotherapy was a major predictor of outcome. 3, 4 Therefore, recent autotransplant trials contain only patients with chemosensitive disease, a highly selected group, making it difficult to determine the overall benefit of ASCT in patients with relapsed and refractory IGL. We have addressed this question by registering relapsed and primary refractory patients on an 'intent-to-treat' program, which encompasses conventional dose second-line chemotherapy followed by high-dose chemoradiotherapy and ASCT for patients with chemosensitive disease, to help define the role of ASCT in the treatment of IGL. We evaluated failure-free survival for all patients whether or not they failed or attained a partial or complete response to conventional-dose second-line chemotherapy.
Because relapse rates post-ASCT range from 30-70%, further refinement of prognostic factors that can predict for a durable remission is essential. A model developed by Vose et al 5 defined good prognosis patients at the time of ASCT as those without a mass Ͼ10 cm and not more than one of the following factors: three or more chemotherapy regimens prior to ASCT, elevated lactate dehydrogenase (LDH) and chemotherapy resistance. This good prognosis group had a 3-year failure-free survival (FFS) of 45%, compared to 10% in the poor prognosis group. Patients who attained a complete remission with conventional-dose second-line chemotherapy prior to ASCT had a better outcome than did patients who had a partial remission prior to ASCT in one study; 6 whereas having a normal LDH and 'limited extent of disease' at the time of ASCT predicted for a better outcome in another study. 7 The International non-Hodgkin's Lymphoma Prognostic Factors Project analyzed 2031 patients with previously untreated IGL who received doxorubicin-based initial chemotherapy, and identified five distinct prognostic factors: age (Ͻ60 vs Ͼ60 years); ECOG performance status (Ͻ1 vs Ͼ2); serum LDH (normal vs elevated); stage (Ann Arbor I/II vs III/IV); and the number of extranodal sites of disease (Ͻ1 vs Ͼ1). These prognostic factors were incorporated into the International Prognostic Index (IPI) which identified four risk groups (having 0 or 1, 2, 3, 4 or 5 adverse risk factors) with 5-year survival rates of 73%, 51%, 43% and 26% respectively. 8 Based on the ability of the IPI to predict for outcome in previously untreated patients, we examined whether the IPI could be used prognostically when applied to patients with relapsed or primary refractory IGL enrolled on an 'intentto-treat' ASCT treatment program. In our group of patients, the IPI determined prior to the initiation of second-line therapy (sIPI), is an excellent predictor of failure-free and overall survival. Most importantly the sIPI appears to further separate the group of patients with chemosensitive disease into distinct good and poor risk subgroups. 
Patients and methods

Patients
Fifty-one transplant-eligible patients were enrolled on Institutional Review Board (IRB) approved protocols for relapsed and refractory IGL or immunoblastic lymphoma (IBL) at Memorial Sloan-Kettering Cancer Center (MSKCC) between 12 October 1993 and 25 July 1995, after obtaining informed consent. A planned interim analysis was conducted after the first 16 patients received the ICEMAN (ifosfamide, carboplatin, etoposide, methotrexate, cytarabine and G-CSF) second-line chemotherapy program and the methotrexate/cytarabine phase was omitted in the subsequent 35 patients (described in Results section).
Eligibility for second-line therapy
All patients were staged according to the Ann Arbor system and histologic review of the original and pre-conventional dose second-line chemotherapy biopsy specimens was performed by one of two expert hematopathologists at MSKCC. Histopathology was classified according to the International Working Formulation. 10 Patients with transformed lymphoma (low-grade lymphoma at initial diagnosis with intermediate-grade or immunoblastic lymphoma at relapse) or discordant histology (presenting originally with both low-grade and either intermediate-grade or immunoblastic lymphoma) were eligible. All patients had a biopsy confirming relapsed or primary refractory IGL or IBL prior to the initiation of ICE-based chemotherapy. Other eligibility criteria included: first relapse and/or primary refractory disease to doxorubicin-based chemotherapy, a normal baseline cardiac function (left ventricular ejection fraction of Ͼ50%), and a serum creatinine р1.5 mg/dl (or creatinine clearance у60 ml/min).
Eligibility for high-dose therapy and autologous stem cell transplantation
Patients were eligible for ASCT if a bone marrow biopsy revealed adequate cellularity and no involvement with large cell lymphoma at the conclusion of ifosfamide, carboplatin and etoposide (ICE)-based chemotherapy. Patients with small cleaved cells in their bone marrow were eligible. Furthermore patients had to have adequate: pulmonary function defined by a DLCO of Ͼ50% of predicted; liver function defined as a serum bilirubin 2 mg/dl; and age Ͻ65 years. Finally all patients had to have achieved a partial or complete response to ICE-based chemotherapy. A complete response was defined as no evidence of disease as documented by restaging 2 weeks after completion of ICE. A conditional complete response was defined as no clinical signs or symptoms of lymphoma, but residual radiographic abnormalities Ͻ2 cm which were inaccessible to biopsy that showed at least a 75% regression in size from the original radiographic study with a normal gallium scan. A partial response was defined as 50% or greater decrease in sum of the products of the diameters of each measurable lesion.
ICE second-line chemotherapy treatment program
Three cycles of ICE chemotherapy were planned at 2-week intervals. The schedule was as follows: etoposide 100 mg/m 2 /day i.v. days 1-3; carboplatin at an AUC 5 (dosed via the Calvert formula: 11 5 ϫ (CrCl ϩ 25) with a maximum dose of 800 mg) on day 2 and ifosfamide 5 g/m 2 mixed with an equal dose of MESNA via continuous infusion for 24 h beginning on day 2. G-CSF (N) was administered at 5 g/kg on days 5-12 for the first two cycles and the dose was increased to 10 g/kg during mobilization of peripheral blood progenitor cells (PBPCs). There were no dose reductions and treatment was delayed until the absolute neutrophil count was Ͼ1000/l and the platelet count was Ͼ50 000/l. CT scans of the chest, abdomen and pelvis were performed prior to the initiation of ICE, after ICE and after MA chemotherapy to evaluate the extent of disease and responsiveness to chemotherapy. Gallium scanning and bone marrow biopsies were done prior to the initiation of ICE, and repeated after ICE and MA chemotherapy if the studies were initially positive.
Transplant conditioning regimens
All patients who underwent ASCT received one of two high-dose conditioning regimens: (1) , and hyperfractionated total body irradiation (TBI) 1375 cGy (125 cGy three times a day, days 1, 2, 4; twice a day, day 3; (18 patients)). In our program we base the choice of the conditioning regimen on the extent of prior radiation therapy. Patients whose prior radiation treatment precluded the use of TBI received CBV.
Involved field radiation therapy (boost radiation therapy) was administered prior to the high-dose conditioning regimen in patients whose residual disease after ICE-based therapy was limited to р2 anatomical regions. The boost radiation was delivered at 150 cGy twice daily fractions to a total dose of 1800 cGy, administered over 6 days in patients who received TBI, or 3000 cGy over 10 days in patients who received CBV. This approach has been uniformly used in this patient population.
International Prognostic Index (IPI)
The International Prognostic Index was based on five prognostic factors with one point given for each unfavorable factor: age Ͼ60 years, LDH Ͼnormal, Ann Arbor stage III or IV, ECOG performance status Ͼ1 (which is equivalent to a Karnofsky performance status Ͻ80%), Ͼ1 extranodal site of disease. In the current analysis E lesions were included as extranodal disease. Patients with 0 or 1 factor were grouped in IPI I (low risk), two factors in IPI II (lowintermediate risk), three factors in IPI III (high-intermediate risk) and four or five factors in IPI IV (high risk). An IPI was determined for all patients at the time of initial diagnosis (iIPI) and at the initiation of second-line therapy (sIPI).
Statistics: hypothesis, and endpoint
The hypothesis of this study was that the IPI, developed for newly diagnosed patients with intermediate-grade lymphoma, when evaluated at the initiation of second-line therapy, is predictive of outcome in relapsed and primary refractory lymphoma patients. The primary endpoint, 'failure-free survival' (FFS), was defined as the time from initiation of ICE-based second-line chemotherapy until treatment failure (which includes neoplastic and non-neoplastic events). Treatment failure occurred if the patient failed to respond to ICE-based second-line chemotherapy, or if the patient relapsed or had progression of disease following high-dose therapy and ASCT.
Statistical methodology
Survival analyses were performed using the method of Kaplan and Meier 13 to obtain estimates of median survival for the various IPI prognostic groups. The log-rank test was used to compare the survival distributions of the IPI groups. Based on Kaplan-Meier curves for all four sIPI groups, the first two categories were grouped together, and the second two categories were grouped together, forming a '2-category second-line IPI.' [14] [15] [16] 
Results
Patient characteristics
Fifty-one patients with relapsed or primary refractory IGL were analyzed on the basis of an 'intention to proceed to ASCT'. Patient characteristics are given in Table 1 . The median age at the initiation of second-line therapy was 48 years. The median follow-up of the surviving patients is 2.5 years (range off-therapy is 28-46 months).
The first 16 patients received ICEMAN chemotherapy, whereas the subsequent 35 patients were treated with ICE alone (see below for further explanation). Seventeen patients received boost radiotherapy (dose of 1800-3000 cGy) to residual bulky disease as dictated in the protocol. 
Treatment outcome
The Kaplan-Meier estimate of the proportion of patients remaining failure-free at 2.5 years after they began ICEbased chemotherapy is 29% ( Figure 1) ; with an estimated overall survival at 2.5 years of 41%. The estimated FFS at 2.5 years for the 34 patients who underwent ASCT is 47% (Figure 1 ), similar to the results reported previously by us and others. 4, [17] [18] [19] One patient who received a PBPC transplant had an early toxic death, secondary to pulmonary hemorrhage; this patient is included in all analyses. Patients with chemosensitive relapsed disease had similar outcomes to patients with chemosensitive primary refractory disease with ASCT (FFS 45% vs 40%; P ϭ 0.42). 
Response to ICE-based second-line chemotherapy
Thirty-five of 51 patients responded to ICE-based chemotherapy (69%); there were nine complete responders, 26 partial responders and 16 non-responders. These 35 patients were eligible to proceed to high-dose therapy. One patient with chemosensitive disease refused to proceed to highdose therapy. All 51 patients are included in our analyses. Patients with primary refractory disease had a response rate of 58% (15/26) vs 80% (20/25) for patients with relapsed disease.
Among the first 16 patients who received ICEMAN, three patients who had partial responses to ICE had progression of disease prior to the initiation of high-dose therapy. In contrast, no patients who had attained less than a partial response to ICE were converted to transplant eligibility as a consequence of the five weekly cycles of MA. This led to a protocol amendment and the elimination of the five weekly cycles of methotrexate and cytarabine from our conventional-dose second-line chemotherapy program. Table 2 Response rate separated by sIPI There was an improved overall survival at 2.5 years in patients attaining a complete or partial response to ICE vs ICE failures (57% vs 6%; long rank P Ͻ 0.001). There was a trend towards improved FFS among patients achieving a complete response to ICE-based chemotherapy compared to those attaining a partial response (log-rank P ϭ 0.09; proportion of patients remaining failure-free at 2.5 years 67% vs 35%) (Figure 2 ).
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International Prognostic Index as a predictor of outcome
We investigated whether the sIPI would predict for time to treatment failure for the ICE-ASCT 'intent to treat' program. As seen in Figure 3a , the outcomes in patients with sIPI low risk (sIPI I) or low-intermediate risk (sIPI II) scores are similar and the curves are not statistically distinguishable. The same is true for patients with high-intermediate (III) or high-risk disease (IV) although these patients do significantly worse than those do with sIPI I and II disease. Thus, we simplified the analysis by comparing sIPI I/II patients vs sIPI III/IV (Figure 3b ). Twentyfour of 29 patients with sIPI I/II disease responded to ICEbased chemotherapy vs 11 of 22 patients with sIPI III/IV disease (see Table 2 ). Kaplan-Meier estimates of the proportion of patients remaining failure-free at 2.5 years for patients with sIPI I or II disease is 45% compared to 9% in patients with sIPI III or IV disease (P Ͻ 0.001). When the analysis is restricted to the subset of patients who received an ASCT, those with sIPI I and II disease have a superior FFS at 2.5 years compared to the patients with sIPI III and IV disease (59% vs 20%, P ϭ 0.04) ( Figure  3c) . Thus, the sIPI is a significant predictor of outcome even for patients with chemosensitive disease.
Given the obvious desirability of predicting treatment outcomes as early as possible, we examined whether the IPI measured at time of initial doxorubicin-based chemotherapy (iIPI) correlated with the sIPI. As depicted in Figure 4a , patients with an iIPI of I tended to have a good prognosis sIPI, whereas patients with an iIPI of IV tended to have a poor prognosis sIPI. The correlation was not as good for patients with IPI II and III disease. Overall, the correlation coefficient between the iIPI and the sIPI was 0.59 (P Ͻ 0.001). Analyzing the results of the ICE-ASCT program according to the iIPI, we found that the iIPI was not predictive of FFS post-ASCT (Figure 4b) .
In order to investigate whether differences in outcome for different sIPI groups were confounded by the effect of the different second-line treatment regimens (written into IRB-approved protocols as described above), the distribution of patients who received ICE vs ICEMAN regimens was examined over the IPI categories. A survival analysis controlling for the second-line regimen was possible only for the group who received ICE, in which there were 14 patients with sIPI I/II disease and 21 patients with sIPI III/IV disease; the survival curves for these groups appeared distinct (P ϭ 0.03). In addition, there was no difference in the FFS curves for the 15 sIPI I/II patients who received ICEMAN vs the 14 sIPI I/II patients who received ICE (P ϭ 0.24). A similar comparison of sIPI III/IV was not possible because only one patient who received ICE-MAN had sIPI III/IV disease. The power of these comparisons is limited because of small samples.
A stratified survival analysis was also performed on sIPI I/II vs sIPI III/IV comparison, controlling for whether a patient had relapsed or primary refractory disease although the subsets are small and the results may be unstable (for the n ϭ 26 refractory patients, P Ͻ 0.001 for the comparison of the survival curves of the sIPI I/II groups and the sIPI III/IV groups; for the n ϭ 25 relapsed patients, P ϭ 0.04 for the same comparisons). Relapsed and primary refractory patients were fairly evenly distributed over sIPI I/II and sIPI III/IV so a confounding effect due to relapsed/primary refractory status is unlikely (Tables 2  and 3) .
Finally, a stratified survival analysis was not performed in order to investigate the difference in transplant conditioning regimens (TBI vs non-TBI) since this subset is too small to break down further (n ϭ 34). However, there 566 has never been a prospective randomized trial showing superiority of one transplant conditioning regimen over another.
Discussion
Multiple confirmatory phase II studies, have demonstrated that high-dose therapy with ASCT can cure a subset of patients with chemoresponsive IGL [18] [19] [20] and the recently published Parma study, a randomized trial comparing six cycles of DHAP (dexamethasone, high-dose cytarabine and cisplatin) chemotherapy vs two cycles of DHAP followed by high-dose therapy and ABMT, clearly demonstrated that high-dose therapy and ABMT improves event-free and overall survival in patients with chemotherapy-sensitive relapsed IGL. 2 Currently, most transplant centers in the USA use chemosensitivity as a prerequisite for ASCT eligibility in patients with relapsed IGL.
Although 50-60% of patients with relapsed or primary refractory IGL have chemosensitive disease, only 30-50% of these chemosensitive patients are currently cured with ASCT. Identifying potential prognostic factors which play a role in survival is critical, since only a minority of patients with chemosensitive disease are being cured. Three recent studies have been published attempting to define prognostic factors in addition to chemosensitivity that can predict survival following ASCT for IGL. 6, 7, 20 Kruek et al 7 evaluated 80 patients with slowly responding or relapsed IGL after front-line therapy and determined that poor prognostic features at the time of ASCT included: an elevated LDH, advanced stage, extranodal disease and a high Coiffer index. A Canadian study evaluated 81 patients with chemosensitive disease and determined that remission status was the only important predictor of progression-free survival (PFS). Patients that attained a complete response to conventional-dose salvage therapy had PFS of 61% at 4 years vs 25% for patients who achieved a partial response; however the definition of complete response can be difficult and in this study gallium scan results are not reported.
A series of 136 NHL patients from the University of Rochester were analyzed to identify prognostic factors for long-term survival. They determined that patients entering an ASCT with minimal disease (defined as all areas р2 cm) had a 5-year event-free survival of 40% vs 26% for those entering the ASCT with bulky disease. However, none of these three studies was based on intention to treat and therefore they apply only to patients with chemosensitive disease. The critical question of curability pre-conventionaldose second-line chemotherapy has been addressed in our intention to treat program.
The International Prognostic Index study identified a number of readily determined clinical and laboratory indices that could divide a large population of patients into four groups of almost equal size. This model was derived from a subset of a large patient experience and proved reliable for the whole population studied. We hypothesized that these same factors may be important at the initiation of second-line therapy. We have analyzed our 51 patients according to both the IPI and as presented above; the sIPI distinctly categorized patients into a favorable group (IPI I/II) and an unfavorable group (IPI III/IV). The KaplanMeier estimate of the proportion of patients enrolled on our 'intent-to-treat' program that remains failure-free at 2.5 years is 29%. We determined that the sIPI defines two separate groups with distinct outcomes. In an intent-to-treat analysis that includes second-line chemotherapy followed by high-dose therapy and ASCT, patients with a poor prognosis, (sIPI III/IV disease) have a small chance (only 9%) of long-term remission. In contrast, favorable patients (sIPI I/II) have a good chance (45% via intention to treat and 59% in patients with chemosensitive disease) of longterm remission.
Our data support the conclusion that the ICE-ASCT approach was effective for favorable patients with a sIPI of I or II. Unfortunately, alternative approaches are needed for patients who have poor prognostic features prior to the initiation of second-line therapy.
One approach would be to alter the initial therapy offered to these patients. Data from multiple institutions using conventional doxorubicin-based treatment programs have shown that approximately 20-25% of patients with IPI IV (high risk) disease at diagnosis can be cured. 21 Since we found a high correlation between sIPI and iIPI, it would be reasonable to evaluate the role of high-dose therapy with stem cell transplantation in patients with poor prognostic features at initial diagnosis. [22] [23] [24] [25] Although chemosensitivity has long been considered the key criterion for proceeding to ASCT, the prognostic factors detailed in this study permit earlier identification of patients with relapsed and primary refractory IGL likely to benefit from conventional-dose second-line therapy and ASCT. High-dose strategies may be improved by the investigation of novel conditioning regimens, or the use of allogeneic stem cell transplantation 26, 27 and should be considered for patients with sIPI III or IV disease. Alternative strategies employing biological agents such as rituximab or radioimmunoconjugates should also be explored in this unfavorable patient population. 28 
